First Week of TRVI February 2026 Options Trading

Trevi Therapeutics (TRVI) is presented with two options strategies: selling a $10.00 put (bid $0.45) would commit purchase at $10.00 resulting in a net cost basis of $9.55 versus the current stock price of $12.45, with a 74% probability the put expires worthless and a 4.50% cash-return (26.07% annualized) YieldBoost. Alternatively, selling a $13.00 covered call (bid $1.20) against shares bought at $12.45 yields a 14.06% total return to Feb 2026 if called, a 43% chance of expiring worthless and a 9.64% (55.84% annualized) YieldBoost; implied volatilities are 148% (put) and 134% (call) versus a 12‑month realized volatility of 70%.

Analysis

Market structure: Elevated option implied vol (puts 148%, calls 134%) versus trailing realized vol ~70% signals outsized demand for downside protection/speculation in TRVI (IV–RV gap ~78pt; IV/RV ≈2.1). Short-premium sellers, covered-call income buyers and market-makers collecting spreads benefit if IV compresses; pure long-equity holders and late-stage buyers lose if vol collapses and stock gaps on binary news. The small‑cap biotech bucket and related ETFs will amplify flows — large put assignment could force supply into the cash equity and widen spreads.

Risk assessment: Tail risk is dominated by biotech binary outcomes (FDA/clinical), financing dilution and rapid liquidity swings; a negative result or failure to secure funding could send TRVI sub-$5 ( >60% downside) in days. Immediate (days) risk: gamma and IV spikes around any announced readout; short-term (weeks/months): IV mean‑reversion of 30–100 pts possible; long-term depends on pipeline outcomes and cash runway. Hidden dependency: open interest concentration and short interest can exacerbate moves if options are exercised/assigned.

Trade implications: Given the IV premium, selling volatility is asymmetric — consider selling-to-open Feb‑2026 TRVI $10 puts for $0.45 only if prepared to acquire at $9.55 (limit position 1–2% NAV); alternatively buy stock at $12.45 and sell Feb‑2026 $13 calls for $1.20 (covered call, 14.06% to expiry) to harvest YieldBoost. To limit tail risk, prefer put-debit spreads (sell $10 / buy $7.50) or iron‑condors instead of naked puts; cut losses if IV compresses >30 pts or price breaks below $9 within 30 days.

Contrarian angles: Consensus focuses on income from selling premium but understates binary upside — a positive trial could double TRVI and vaporize short-premium profits. Historical parallel: post-readout biotech IV collapses (200–400% realized moves vs prior implied) show sellers get hurt if they lack defined downside protection. Action trigger: if IV/RV ratio falls below 1.2 or IV falls by >30 pts, flip strategy from short‑vol to long‑equity or long‑calls within 7 trading days.

Key Decisions for Investors

• Sell-to-open TRVI Feb‑2026 $10 put for $0.45 (effective buy price $9.55) size 1–2% NAV; only if willing to own shares at $9.55. Hedge tail risk by simultaneously buying the Feb‑2026 $7.50 put (put debit spread) and close trade if TRVI < $8.50 or paper loss >30%.
• Establish a covered-call: buy TRVI at market (~$12.45) and sell Feb‑2026 $13 call for $1.20 size 1% NAV (caps upside to $13 for 14.06% to expiry). Exit/roll if IV drops >30 pts or stock rallies >15% before expiry.
• If preferring pure volatility sell, implement an iron‑condor: sell Feb‑2026 $10 put / buy $7.50 put and sell Feb‑2026 $16 call / buy $18 call to collect premium and define max loss; max allocation 0.5–1% NAV and close if IV/RV ratio <1.2.
• Monitor next 30–90 days for any clinical/readout/regulatory dates, cash‑raise announcements, or large OI shifts; if IV declines by >30 pts or IV/RV ratio falls below 1.2, unwind short‑vol positions and redeploy into selective long calls (3–6 month tenor).